Interferon Î²-1a decreased the risk for conversion to clinically definite/multiple sclerosis
- news. // Inside MS;Oct-Dec2002, Vol. 20 Issue 4, p25
Presents an update on issues concerning multiple sclerosis in the U.S. as of October 2002. Medicare coverage for Avonex interferon drug; Findings of a study on interferon; Highlights of a meeting held by the American Academy of Neurology.
- Blockade of gamma interferon might be beneficial in MS. Steinman, L. // Multiple Sclerosis (13524585);Oct2001, Vol. 7 Issue 5, p275
Comments on the application of the blockade of gamma interferon in the treatment of multiple sclerosis. Clinical trial of copaxone; Tests conducted on other antibody treatment; Failure in the trial of anti-tumor necrosis factor approach.
- International consensus statement on the use of disease-modifying agents in multiple sclerosis. Freedman, M S; Blumhardt, L D; Brochet, B; Comi, G; Noseworthy, J H; Sandberg-Wollheim, M; Soelberg S�rensen, P // Multiple Sclerosis (13524585);Feb2002, Vol. 8 Issue 1, p19
Objective: To provide recommendations on the use of disease-modifying agents in the management of multiple sclerosis (MS) and to ensure that treatment will be available to those patients who may benefit. Methods: An initial draft of the consensus statement was prepared by the Steering Committee...
- Interferon-ï¿½ dose and efficacy: the OPTIMS study. Durelli, L.; Oggero, A.; Verdun, E.; Barbero, P.; Pipieri, A.; Isoardo, G.; Ricci, A.; Clerico, M.; Bradac, G.; Bergamasco, B.; Bergui, M. // Neurological Sciences;Apr2001, Vol. 22 Issue 2, p201
Interferon beta (IFN-ï¿½) reduces exacerbation rates in patients with relapsing-remitting multiple sclerosis (MS), but some patients do not respond to treatment. Recent studies have shown a clear dose-response effect on the reduction of exacerbation rates, and on burden of disease...
- Implication of the Toll-like receptor 4 pathway in the response to interferon-ï¿½ in multiple sclerosis. // Current Medical Literature: Multiple Sclerosis;2012, Vol. 4 Issue 1, p19
An abstract of the article "Implication of the Toll-like receptor 4 pathway in the response to interferon-ï¿½ in multiple sclerosis," by M. F. Bustamante, and colleagues is presented.
- Interferon Beta May Not Reduce Disability Progression for Patients With MS. // Neurology Reviews;Aug2012, Vol. 20 Issue 8, p22
The article presents information on study according to which treatment with interferon beta medicine was not associated with reduced progression of disability in relapsing-remitting multiple sclerosis patients.
- Recombinant Interferon-Î²-1a: A Review of its Therapeutic Efficacy in Relapsing-Remitting Multiple Sclerosis. Wagstaff, A.J.; Goa, K.L. // BioDrugs;1998, Vol. 10 Issue 6, p471
This review focuses on Rebif, one of 2 available formulations of recombinant interferon-Î²-1a, a molecule with the same molecular weight and primary structure as native interferon-Î². The product under review is intended for subcutaneous injection and contains 22 or 44Âµg of recombinant...
- Treatment of Multiple Sclerosis with the Interferon-Î²s: Comparative Risks and Benefits. Herndon, R.M. // BioDrugs;1998, Vol. 10 Issue 6, p463
Several inteferons (IFNs) have recently been introduced for the treatment of multiple sclerosis (MS). These are IFNÎ²-1b (Betaseron) and 2 IFNÎ²-1a preparations (Avonex and Rebif). All 3 drugs reduce the number of acute exacerbations in relapsing remitting MS by about one-third but, because...
- Appropriate Use of Interferon Beta-1a in Multiple Sclerosis. Jacobs, L.; Brownscheidle, C.M. // BioDrugs;1999, Vol. 11 Issue 3, p155
Multiple sclerosis (MS), a chronic inflammatory demyelinating disease of the central nervous system, is the most common crippling neurological disease of young adults in the US. The 2 basic clinical forms of the disease (relapsing and progressive), which can occur singly or in combination,...
- Multipl Skleroz HastalarÄ±nda Ä°nterferon Beta 1-bâ€™nin SaÄŸkalÄ±m Ãœzerine Etkisi. Kürtüncü, Murat // Turkish Journal of Neurology / Turk Noroloji Dergisi;Jun2013, Vol. 19 Issue 2, p76
No abstract available.